Zoetis Inc. (ZTS) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A indicate a generally positive outlook. The company raised its guidance for revenue and net income growth, reflecting confidence in its performance. Despite some challenges in specific areas like Librela and OA pain, the company expects stabilization and growth in key franchises. The livestock segment shows strong growth, and international market expansion is promising. Adjusted gross margins have improved, and there is a strategic focus on innovation and market expansion. Overall, the positive aspects outweigh the negatives, suggesting a likely positive stock price movement.
Key Financial Performance
Revenue Growth 4% revenue growth year-over-year, driven by price increases and flat volume. Growth moderated due to strong year-over-year comparison and macro factors like vet clinic visits and promotional activity.
Adjusted Net Income 9% growth in adjusted net income on an organic operational basis, attributed to cost discipline and balanced investment approach.
International Segment Revenue Growth 6% organic operational revenue growth, driven by strong performance in Companion Animal and Livestock segments.
U.S. Revenue Growth 3% organic operational revenue growth, with Companion Animal flat and Livestock growing 14%. Growth impacted by strong prior year comparison and declining vet clinic visits.
Companion Animal Revenue 2% operational growth, driven by Simparica franchise (7% growth) and Key Dermatology (3% growth). Offset by 11% decline in OA pain franchise due to misperceptions and social media impact.
Livestock Revenue 10% organic operational revenue growth, supported by vaccine-led growth in poultry and increased key account penetration.
Simparica Franchise Revenue 7% operational growth, with Simparica Trio contributing 6% growth. Growth driven by international demand and retail/home delivery channels in the U.S.
Key Dermatology Franchise Revenue 3% operational growth, driven by Apoquel Chewable adoption and strong retail performance. Growth offset by clinic softness and competitive dynamics.
OA Pain Franchise Revenue 11% operational decline, with Librela sales declining 15% globally due to misperceptions amplified on social media. Solensia sales declined 4% in the U.S. but grew 9% internationally.
Adjusted Gross Margins 71.6%, an increase of 90 basis points year-over-year, driven by favorable impact of MFA divestiture and price increases.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Simparica Franchise: Grew 7% operationally, with Simparica Trio growing 6% operationally. Internationally, strong double-digit growth driven by Trio's demand and approval in Brazil.
Key Dermatology Franchise: Grew 3% operationally, driven by Apoquel Chewable adoption and strong retail performance. Internationally, growth despite competitive dynamics and new product launches.
OA Pain Franchise: Declined 11% operationally, with Librela sales declining 15% globally due to misperceptions amplified on social media. New products Lenivia and Portela approved in Canada and Europe, respectively, with launches expected in 2026.
Geographic Expansion: Simparica Trio approved in Brazil, Apoquel Chewable approved in Chile, and Cytopoint received an expanded label in Brazil for allergic itch.
Livestock Market: Organic operational revenue grew 10%, driven by poultry vaccine growth, deeper penetration among key accounts, and adoption of Procerta across regions.
Manufacturing Investments: Investments in the Atlanta Advanced Biologics facility and expanded monoclonal antibody production capabilities to support portfolio growth.
U.S. Commercial Structure: Evolving to a leaner, more agile field organization to enhance customer engagement and competitive positioning.
Innovation Pipeline: Over 130 geographic expansion and life cycle innovations in 2025. Anticipating a major new market approval each year for the next several years.
R&D Leadership Transition: Rob Polzer retiring; Kevin Esch appointed as successor to lead R&D from January 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Growth Moderation: Growth moderated this quarter due to strong year-over-year comparisons and macro factors, including reduced vet clinic visits and promotional activity.
Competitive Pressures in U.S. Market: The U.S. market faces increased competition, particularly in parasiticides and dermatology, with aggressive promotional activities and new product launches impacting market share.
Osteoarthritis (OA) Pain Franchise Decline: The OA pain franchise declined 11% operationally, with Librela sales affected by misperceptions amplified on social media, leading to a 15% operational decline globally.
Clinic Traffic Decline: Subdued clinic traffic in the U.S. impacted new patient starts and overall franchise performance, particularly in Companion Animal products.
Regulatory and Market Dynamics: Regulatory approvals and market dynamics in international markets, such as competitive discounting and promotional activities, are creating challenges in maintaining market share.
Supply Chain and Manufacturing Investments: Investments in manufacturing facilities and capabilities are necessary to support growth, but they also represent a financial and operational challenge.
Economic and Macro Uncertainties: A more measured view of macro and operational trends in the back half of the year has led to revised revenue and income growth guidance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: Zoetis has revised its full-year revenue guidance to a range of $9.4 billion to $9.475 billion, reflecting organic operational growth of 5.5% to 6.5%. This adjustment is based on a more measured view of macro and operational trends in the back half of the year.
Adjusted Net Income: The company expects adjusted net income to be in the range of $2.8 billion to $2.840 billion, reflecting a narrowed organic operational growth range of 5.5% to 7%.
Adjusted Diluted EPS: Zoetis is maintaining its reported diluted and adjusted diluted EPS guidance range of $5.90 to $6 and $6.30 to $6.40, respectively.
Companion Animal Segment: The company anticipates continued growth in its Simparica Trio franchise, driven by its first-mover advantage and strong market presence. Dermatology is expected to expand, supported by differentiated products like Apoquel and Cytopoint, despite competitive pressures.
Osteoarthritis Pain Franchise: Zoetis is implementing a multipronged strategy to return Librela to growth, including increased awareness, education, and new product launches. The company is optimistic about the untapped market potential in feline OA, with new products like Portela expected to drive compliance and growth.
Livestock Segment: The Livestock segment is on track for a third consecutive year of above-market growth in 2025, supported by strong execution, vaccine-led growth, and rising protein consumption globally.
Pipeline and Innovation: Zoetis anticipates a major new market approval each year for the next several years, with upcoming launches of Lenivia and Portela in the first half of 2026. The company is also investing in manufacturing capabilities to support its expanding portfolio.
U.S. Commercial Structure: Zoetis is evolving its U.S. commercial structure to better serve customers, aiming for a leaner, more agile field organization. This model is expected to support growth and enhance competitive positioning into 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What meaningfully changed on an intra-quarter basis after raising guidance last quarter?
A:The company saw a macro impact, particularly in U.S. clinics, with therapeutic visits being down for three consecutive quarters. This impacted patient starts and overall growth. Despite this, they factored these dynamics into their guidance and expect stabilization in certain areas like Librela.
Q:How does competition in dermatology impact the company, and is the guidance conservative enough?
A:The company anticipated competitive dynamics, including aggressive promotions, and factored them into their guidance. They believe their guidance is conservative and expect stabilization and growth in key areas like derm and parasiticides. They also highlighted the strong satisfaction with their products, which limits the impact of competition.
Q:What is the outlook for 2026 and its fit into the typical 6%-8% top-line growth guidance?
A:The company expects stabilization in areas like Librela and continued growth in livestock. They do not see the fourth quarter of 2025 as indicative of 2026 performance and will provide detailed guidance in February. They anticipate price contributions in the typical 2%-4% range and are confident in their ability to grow key franchise areas.
Q:What are the intra-quarter dynamics and distributor inventory levels?
A:Therapeutic visits have been down, impacting patient starts, particularly in derm and OA pain. Distributor inventory levels dipped mid-quarter but recovered by the end. The company has been operating at inventory levels below the low end of the range since early 2023.
Q:What changes are expected in the price/volume algorithm for 2026?
A:The company expects stabilization in Librela and believes competitive pressures will be short-lived. They anticipate growth in derm and international markets despite macro challenges. They are confident in their portfolio and innovation pipeline to drive long-term growth.
Q:What are the plans for launching new long-acting OA drugs?
A:The company plans to apply learnings from Librela to new launches like Lenivia and Portela, focusing on early experience with specialists and raising awareness of OA as a serious disease. They expect these drugs to expand the market and provide incremental revenues, with launches planned for the first half of 2026.
Q:What happened with U.S. Derm this quarter, and what is the outlook for therapeutic visits?
A:U.S. Derm faced challenges due to declining therapeutic visits and macroeconomic factors. The company does not expect immediate recovery in therapeutic visits but is encouraged by signs of stabilization in certain areas like Librela. They will update guidance in February.
Q:How sustainable are the growth drivers for livestock?
A:The company is confident in the sustainability of livestock growth, driven by increased demand for protein, population growth, and urbanization. Livestock has shown double-digit growth and outperformed the market for three consecutive years.
Q:What is the impact of distributor inventory dynamics and competition on derm performance?
A:Distributor inventory dynamics had minimal impact, with a $10 million contribution from Apoquel. Competitive pressures from Zenrelia and NUMELVI are limited and in line with expectations. The company remains confident in its strong market position.
Q:How is the Simparica Trio franchise performing, and what are the plans for new canine parasiticides?
A:Simparica Trio faced tough comps but maintained its market share. The company sees significant room for growth in the flea, tick, and heartworm market. They plan to provide updates on new canine parasiticides during their December 2 innovation webcast.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer on the exact timing of recovery for therapeutic visits and the specific impact of macroeconomic factors on future performance. They also did not provide detailed guidance for 2026, deferring it to February.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Advanced Biologics
Adviser end
Atlanta Advanced
Biologics facility
Brazil itch
Brazil momentum
CVMP opinion
Canada launch
Chile label
Esch
Lenivia
Portela
RD
Tuesday
antibody
approach
comp
convenience
disease
engagement
engine
example
expansion life
experience
flexibility
investor
life cycle
market approval
market expansion
market portfolio
model
position
practice
reach
region
role
specialist
strength franchise
structure
term trajectory
update progress
ZTS Transcript
Zoetis Inc. (ZTS) Presents at 46th Annual William Blair Growth Stock Conference Transcript
Neutral6-2
Zoetis Inc. (ZTS) Presents at Stifel Jaws & Paws Conference 2026 Transcript
Neutral5-28
Zoetis Inc. (ZTS) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call presents a mixed picture. Despite some positive growth in international revenue and livestock, U.S. revenue declined due to competition and market contraction. The Q&A section highlights management's strategies to address challenges but lacks specific details, leading to uncertainties. While there is optimism in product innovation and market expansion, the competitive pressures and affordability issues remain concerns. Given these factors, the stock price is likely to remain stable, resulting in a neutral sentiment.
Zoetis Inc. (ZTS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-10
ZTS Slides
ZTS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
